Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
149 USD | -0.83% | +0.74% | -22.16% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 19B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.48 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.2 x |
P/E ratio 2024 * |
-42.5
x | P/E ratio 2025 * |
-80.7
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | +0.56% | ||
1 week | +0.23% | ||
Current month | +4.37% | ||
1 month | +4.04% | ||
3 months | +0.37% | ||
6 months | -9.09% | ||
Current year | -21.51% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | +0.15% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 149 | -0.83% | 332 171 |
24-05-20 | 150.2 | +0.56% | 368,554 |
24-05-17 | 149.4 | -1.20% | 481,247 |
24-05-16 | 151.2 | +2.59% | 934,860 |
24-05-15 | 147.4 | -0.33% | 536,143 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.51% | 19B | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.67% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B | |
-5.64% | 11.49B |
- Stock Market
- Equities
- ALNY Stock